CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 687 enrolled
Drug / intervention
Neupro®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01113710
NCT01113710N/ACompleted

Non-Interventional Study (NIS) in Patients With Restless Legs Syndrome (RLS) to Assess the Effectiveness and Safety of Neupro® in Daily Practise

UCB Pharma·observational·Posted Apr 30, 2010·Updated Sep 28, 2012

In Brief

An observational study evaluating Neupro® for Idiopathic Restless Legs Syndrome. Completed, enrolled 687 participants across 80 sites.

Detailed Summary

This non-interventional observational study is designed to gain data for Neupro® in restless legs syndrome (RLS) under real life conditions in line with the summary of product characteristics (SmPC) related to effectiveness, tolerability and switching practice from other dopaminergic drugs as well as titration schemes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 30, 2010
Enrollment StartMay 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.2 years ago

Interventions

Neupro®drug

Neupro® is the exposure/intervention of interest in this non-interventional study.